Form 4: Ionis CFO Sells Shares After Option Exercise

Ionis Pharmaceuticals' EVP, Finance & CFO, Elizabeth L. Hougen, exercised stock options and subsequently sold 49,800 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Elizabeth L. Hougen, Executive Vice President, Finance & Chief Financial Officer of Ionis Pharmaceuticals, Inc. (IONS), engaged in a series of transactions on September 30, 2025.
• Hougen exercised non-qualified stock options to acquire 49,800 shares of common stock at an exercise price of $53.77 per share.
• Immediately following the option exercise, Hougen sold all 49,800 acquired shares of common stock at a weighted average price of $65.2557 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on January 13, 2024.
• After these transactions, Hougen's direct beneficial ownership of Ionis Pharmaceuticals common stock stands at 110,500 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the executive realized a gain, the transaction is a routine insider sale under a pre-arranged 10b5-1 plan, which typically does not signal new information about the company's prospects. It represents a planned liquidity event for the individual.

Positives

• The executive realized a gain from the exercise of stock options and subsequent sale, with the sale price ($65.2557) significantly higher than the exercise price ($53.77).
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, non-public information.

Negatives

• The direct beneficial ownership of common stock by a key executive, Elizabeth L. Hougen, decreased by 49,800 shares following the sale.

Future Outlook

This Form 4 filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This specific insider transaction is a routine disclosure and does not inherently provide broader industry context or competitive insights. It reflects an individual executive's financial planning rather than a strategic industry move.

Stakeholder Impact

• Shareholders may note the reduction in direct beneficial ownership by a key executive, though the pre-scheduled nature of the sale under a 10b5-1 plan mitigates concerns about its implications for company performance.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Elizabeth L. Hougen, CFO, 10b5-1 Plan, Beneficial Ownership